Logo image of ATYR

ATYR PHARMA INC (ATYR) Stock Fundamental Analysis

NASDAQ:ATYR - Nasdaq - US0021202025 - Common Stock - Currency: USD

5.31  +0.03 (+0.57%)

After market: 5.19 -0.12 (-2.26%)

Fundamental Rating

2

ATYR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. The financial health of ATYR is average, but there are quite some concerns on its profitability. ATYR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATYR has reported negative net income.
ATYR had a negative operating cash flow in the past year.
In the past 5 years ATYR always reported negative net income.
In the past 5 years ATYR always reported negative operating cash flow.
ATYR Yearly Net Income VS EBIT VS OCF VS FCFATYR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -65.21%, ATYR is doing worse than 62.16% of the companies in the same industry.
ATYR has a Return On Equity (-84.49%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -65.21%
ROE -84.49%
ROIC N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ATYR Yearly ROA, ROE, ROICATYR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATYR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATYR Yearly Profit, Operating, Gross MarginsATYR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATYR has been increased compared to 1 year ago.
Compared to 5 years ago, ATYR has more shares outstanding
Compared to 1 year ago, ATYR has an improved debt to assets ratio.
ATYR Yearly Shares OutstandingATYR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATYR Yearly Total Debt VS Total AssetsATYR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ATYR has an Altman-Z score of 3.52. This indicates that ATYR is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.52, ATYR is in the better half of the industry, outperforming 73.87% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that ATYR is not too dependend on debt financing.
ATYR has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 3.52
ROIC/WACCN/A
WACC9.63%
ATYR Yearly LT Debt VS Equity VS FCFATYR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 7.79 indicates that ATYR has no problem at all paying its short term obligations.
ATYR has a Current ratio of 7.79. This is in the better half of the industry: ATYR outperforms 69.37% of its industry peers.
ATYR has a Quick Ratio of 7.79. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
ATYR has a better Quick ratio (7.79) than 69.73% of its industry peers.
Industry RankSector Rank
Current Ratio 7.79
Quick Ratio 7.79
ATYR Yearly Current Assets VS Current LiabilitesATYR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

ATYR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.00%, which is quite good.
The Revenue for ATYR has decreased by -100.00% in the past year. This is quite bad
The Revenue for ATYR have been decreasing by -11.05% on average. This is quite bad
EPS 1Y (TTM)10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.09%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%-100%

3.2 Future

ATYR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.65% yearly.
ATYR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 388.98% yearly.
EPS Next Y23.53%
EPS Next 2Y12.05%
EPS Next 3Y33.06%
EPS Next 5Y42.65%
Revenue Next Year1221.14%
Revenue Next 2Y1251.95%
Revenue Next 3Y810.96%
Revenue Next 5Y388.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATYR Yearly Revenue VS EstimatesATYR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATYR Yearly EPS VS EstimatesATYR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATYR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATYR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATYR Price Earnings VS Forward Price EarningsATYR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATYR Per share dataATYR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ATYR's earnings are expected to grow with 33.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.05%
EPS Next 3Y33.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATYR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATYR PHARMA INC

NASDAQ:ATYR (7/3/2025, 7:03:18 PM)

After market: 5.19 -0.12 (-2.26%)

5.31

+0.03 (+0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners69.69%
Inst Owner ChangeN/A
Ins Owners2.21%
Ins Owner Change8.22%
Market Cap472.59M
Analysts83.53
Price Target18.3 (244.63%)
Short Float %15.68%
Short Ratio6.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.1%
Min EPS beat(2)12.28%
Max EPS beat(2)21.92%
EPS beat(4)3
Avg EPS beat(4)9.24%
Min EPS beat(4)-2.5%
Max EPS beat(4)21.92%
EPS beat(8)6
Avg EPS beat(8)9.28%
EPS beat(12)9
Avg EPS beat(12)11.6%
EPS beat(16)10
Avg EPS beat(16)6.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.01%
PT rev (3m)-4.01%
EPS NQ rev (1m)1.14%
EPS NQ rev (3m)4.85%
EPS NY rev (1m)0.04%
EPS NY rev (3m)6.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-22.24%
Revenue NY rev (3m)-28.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.3
P/tB 6.3
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS0.84
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.21%
ROE -84.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.89%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.79
Quick Ratio 7.79
Altman-Z 3.52
F-Score3
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)476.17%
Cap/Depr(5y)300.89%
Cap/Sales(3y)412.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.09%
EPS Next Y23.53%
EPS Next 2Y12.05%
EPS Next 3Y33.06%
EPS Next 5Y42.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%-100%
Revenue Next Year1221.14%
Revenue Next 2Y1251.95%
Revenue Next 3Y810.96%
Revenue Next 5Y388.98%
EBIT growth 1Y-14.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.72%
EBIT Next 3Y29.4%
EBIT Next 5Y32.65%
FCF growth 1Y-76.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.1%
OCF growth 3YN/A
OCF growth 5YN/A